Texas A&M researchers have identified an experimental small-molecule inhibitor called GPPD that targets the MAP4K4 protein, successfully reducing fat accumulation, inflammation, liver injury, and fibrosis in preclinical models of metabolic dysfunction-associated steatohepatitis.
For millions of people living with metabolic dysfunction-associated steatohepatitis, treatment options remain limited. This advanced form of fatty liver disease starts when too much fat builds up in the liver, triggering inflammation, cellular injury, and fibrosis—scar tissue accumulation that can ultimately progress to cirrhosis, liver failure, and transplant requirements. Although the first medications for the condition have recently become available, they are only intended for patients with advanced disease and carry common side effects.
Targeting MAP4K4 and the GPPD Compound
Rather than focusing on traditional therapeutic targets, researchers at the Texas A&M College of Veterinary Medicine and Biomedical Sciences investigated MAP4K4, a protein involved in several major biological pathways. Because the protein acts as a central regulator of multiple disease-related processes, researchers believed it could have broader effects on liver disease. Analyses determined that MAP4K4 levels increased as the condition advanced, suggesting it could serve as a promising new target for therapy.
Working with collaborators at the University of Oklahoma, the research team tested an experimental small-molecule inhibitor called GPPD. Rather than reducing the amount of MAP4K4 present, the compound targets and inhibits its function, which could keep the protein’s standard activities intact while lessening its pathological impact.
MAP4K4 is a master regulator that influences multiple biological pathways involved in fat accumulation and disease progression. GPPD is unique because it decreases the protein’s activity without changing its overall levels, which may help preserve its normal functions while still providing therapeutic benefit.
Addressing Multiple Hallmarks of Disease Simultaneously
The investigators found that GPPD improved several defining characteristics of the disease simultaneously, including fat accumulation, inflammation, liver injury, and fibrosis. Many experimental therapies focus on only one aspect of the condition, such as reducing fat buildup in the liver. Yet, because scientists now understand that the condition advances via a network of linked biological mechanisms, an effective cure demands intervention across multiple symptoms simultaneously rather than focusing on just one.
In laboratory studies, researchers treated mice that had been fed a high-fat diet to simulate fatty liver disease with GPPD. They found that GPPD reduced fat accumulation, inflammation, liver injury and fibrosis in these mice, while also significantly decreasing hepatic triglyceride and cholesterol levels.
Testing in Human Liver Tissue
Beyond preclinical models, the research team tested GPPD in human liver tissue obtained from five healthy controls and 20 patients diagnosed with metabolic dysfunction-associated steatotic liver disease and no history of alcohol use. The analysis revealed that MAP4K4 expression was higher in the livers of patients with the disease than in livers from healthy individuals, reinforcing the protein’s relevance as a therapeutic target in human patients.
Safety Profiles and Path to Clinical Testing
Beyond its effectiveness in preclinical trials, the experimental therapy demonstrated an encouraging safety profile. The research team conducted extensive toxicology studies and found no evidence of significant toxicity, marking an important milestone as the treatment moves closer to clinical evaluation.
Before human clinical trials can begin, the research team is completing pharmacokinetic studies to understand how the compound is absorbed, distributed, and processed by the body. These studies will help determine the safest and most effective dose for future trials, while additional investigations explore whether the compound improves liver disease directly or whether some of its benefits result from weight loss observed during treatment.